ARTICLE | Company News
MegaPharm, Pharming sales and marketing update
June 13, 2011 7:00 AM UTC
Pharming granted MegaPharm Israeli commercialization rights to Ruconest conestat alfa to treat acute attacks of hereditary angioedema (HAE). MegaPharm will purchase Ruconest from Pharming at a supply price based on a percentage of net sales. Pharming is eligible for milestones. MegaPharm plans to launch the recombinant human complement 1 (C1) esterase inhibitor in 2012. ...